A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Cytomegalovirus

In brief

The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.

Key facts

Study ID
NCT05575492
Run by
ModernaTX, Inc.
People needed
873
Starts
2022-11-07
Expected to finish
2026-05-12
Last updated by the study team
2026-06-04

Who can join

Age: 9 and older, up to 25. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.